Gras Jordi
Drugs Today (Barc). 2009 Dec;45(12):855-64. doi: 10.1358/dot.2009.45.12.1424267.
Hereditary angioedema (HAE) is an autosomal dominant, potentially life-threatening disease, characterized by recurrent self-limiting bouts of edema mainly involving the extremities, genitalia, face, intestines and airways. The prevalence of HAE in the general population has been estimated to be in the range of 1:10,000 to 1:150,000. Currently, acute attacks of HAE are treated mainly symptomatically, with poor outcomes. Recently, it has been demonstrated that bradykinin (BK) is responsible for most of the symptoms of HAE. Icatibant (Firazyr, HOE 140, JE049) is a potent, specific and selective B2 BK receptor antagonist that has recently been approved by the EMEA for the treatment of HAE. In phase III clinical trials, 30 mg of subcutaneous icatibant demonstrated rapid and stable relief from symptoms in cutaneous, abdominal or laryngeal HAE attacks. Local site reactions after subcutaneous injection of icatibant were observed, however, these reactions were mild to moderate in severity and resolved spontaneously and quickly. Icatibant is a new, safe and effective treatment for acute attacks of HAE.
遗传性血管性水肿（HAE）是一种常染色体显性遗传、可能危及生命的疾病，其特征为反复发作的自限性水肿，主要累及四肢、生殖器、面部、肠道和气道。据估计，普通人群中HAE的患病率在1:10,000至1:150,000之间。目前，HAE的急性发作主要采用对症治疗，效果不佳。最近有研究表明，缓激肽（BK）是导致HAE大部分症状的原因。依卡替班（Firazyr，HOE 140，JE049）是一种强效、特异性和选择性的B2 BK受体拮抗剂，最近已获欧洲药品管理局（EMEA）批准用于治疗HAE。在III期临床试验中，30 mg皮下注射依卡替班可使皮肤、腹部或喉部HAE发作的症状迅速且稳定地缓解。皮下注射依卡替班后观察到有局部反应，不过这些反应的严重程度为轻至中度，且可自发并迅速消退。依卡替班是一种治疗HAE急性发作的新型、安全且有效的药物。
